Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer

Journal of the American College of Surgeons

Volumn 212, Issue 6, 2011, Pages

  Chen, Zhenbin ^a   Duldulao, Marjun P ^a   Li, Wenyan ^a   Lee, Wendy ^a   Kim, Joseph ^a   Garcia Aguilar, Julio ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM CANCER; RECTUM RESECTION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR REGRESSION;

EID: 79957610467     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2011.02.024     Document Type: Article

References (48)

1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
2. Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The MD Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999;44:1027-1038. (Pubitemid 29342903)
3. Pucciarelli S, Toppan P, Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 2004;47:1798-1807. (Pubitemid 40064422)
4. Chari RS, Tyler DS, Anscher MS, et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995;221:778-786.
5. Diaz-Gonzalez JA, Calvo FA, Cortes J, et al. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. Int J Radiat Oncol Biol Phys 2006;64:1122-1128.
6. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-8696. (Pubitemid 46211512)
7. Valentini V, Coco C, Picciocchi A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002;53: 664-674. (Pubitemid 34626505)
8. Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:752-760. (Pubitemid 40779765)
9. Borschitz T, Wachtlin D, Mohler M, et al. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol 2008;15:712-720.
10. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathologic complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835-844.
11. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240: 711-717.
12. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:429-435.
13. Kim J, Reber HA, Dry SM, et al. Unfavorable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 2006;55:1598-1605. (Pubitemid 44629210)
14. van Houten VM, Leemans CR, Kummer JA, et al. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 2004; 10:3614-3620. (Pubitemid 38697594)
15. Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003;63:1727-1730. (Pubitemid 36460827)
16. Tabor MP, Brakenhoff RH, Ruijter Schippers HJ, et al. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res 2004;10:3607-3613. (Pubitemid 38697593)
17. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
18. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-684.
19. Andreyev HJN, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001;85:692-696.
20. Di-Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96: 1166-1169.
21. Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19:299-304.
22. Goh HS, Elnatan J, Low CH, Smith DR. p53 point mutation and survival in colorectal cancer patients: effect of disease dissemination and tumour location. Int J Oncol 1999;15:491-498.
23. Lievre A, Bachet JB, Le-Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995.
24. Luna-Perez P, Arriola EL, Cuadra Y, et al. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol 1998;5:203-208. (Pubitemid 28249307)
25. Rebischung C, Gerard JP, Gayet J, et al. Prognostic value of P53 mutations in rectal cancer. Int J Cancer 2002;100:131-135. (Pubitemid 34666184)
26. Russo A, Bazan V, Iacopetta B, et al. The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J ClinOncol 2005;23:7518-7528.
27. Soong R, Powell B, Elsaleh H, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000;36:2053-2060.
28. Garcia-Aguilar J, Smith DD., Avila K, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a prospective trial. Ann Surg. 2011. doi:10.1016/j.jamcollsurg.2011.02.024.
29. Edge SB, Compton CC, Fritz AG, et al. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. Chicago, IL: Springer, Inc; 2010.
30. Dabritz J, Hanfler J, Preston R, et al. Detection of K-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridization probes. Br J Cancer 2005;92:405-412. (Pubitemid 40343159)
31. Gilje B, Heikkila R, Oltedal S, et al. High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations. J Mol Diagn 2008;10:325-331. (Pubitemid 352019118)
32. Luo JD, Chan EC, Shih CL, et al. Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res 2006;34:e12.
33. Taback B, Bilchik AJ, Saha S, et al. Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer 2004;111: 409-414. (Pubitemid 38998822)
34. Thiede C, Bayerdorffer E, Blasczyk R, et al. Simple and sensitive detection of mutations in the Ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 1996; 24:983-984. (Pubitemid 26076209)
35. Shi J, Liu Q, Sommer SS. Detection of ultrarare somatic mutation in the human TP53 gene by bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification. Hum Mutat 2007;28:131-136. (Pubitemid 46233309)
36. Liu Q, Sommer SS. Pyrophosphorolysis-activatable oligonucleotides may facilitate detection of rare alleles, mutation scanning and analysis of chromatin structures. Nucleic Acids Res 2002; 30:598-604. (Pubitemid 34679623)
37. Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327:298-303. (Pubitemid 17075080)
38. Spitz FR, Giacco GG, Hess K, et al. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 1997;3: 1685-1690.
39. Yashiro M, Inoue T, Nishioka N, et al. Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma. Ann Surg Oncol 2009;16:2926-2935.
40. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361: 2449-2460.
41. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217-4219.
42. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-2714. (Pubitemid 39665324)
43. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27:2622-2629.
44. Vincent-Salomon A, Jouve M, Genin P, et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002;94:2169-2173. (Pubitemid 34411973)
45. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-689. (Pubitemid 35232337)
46. Lips EH, van-Eijk R, de-Graaf EJR, et al. Progression and tumor heterogeneity analysis in early rectal cancer. Clin Cancer Res 2008;14:772-781.
47. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2009;26:3213-3221.
48. Smerage JB, Hayes DF. The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer 2006;94:8-12. (Pubitemid 43088533)